Hallmarks of Cancer 2026: The Systemic Era

· 2 min read · Paper Feed

Hallmarks of Cancer 2026: The Systemic Era

It’s been 25 years since Hanahan and Weinberg first published The Hallmarks of Cancer, giving us the six (later ten) principles that defined how we understand tumorigenesis.

This week, Douglas Hanahan released the 2026 update in Cell: "Hallmarks of Cancer—Then and Now, and Beyond."

While the core hallmarks (like evading growth suppressors and resisting cell death) remain, the focus has shifted dramatically outward. We are no longer just looking at a "rebellious cell" or even a "tumor microenvironment." We are looking at a systemic disease.

Figure 1: The updated Hallmarks of Cancer framework. Source: Hanahan, Cell 2026 (CC BY 4.0)

What's New in 2026?

1. The "Clouds of Complexity": Systemic Interactions

The biggest addition is the formal integration of systemic factors—what Hanahan calls "clouds of complexity." Cancer doesn't exist in a vacuum; it interacts with the entire organism.

  • Aging: Not just a risk factor, but a systemic state that enables cancer.
  • Obesity & Metabolism: Systemic metabolic dysregulation fuels the tumor.
  • Neuro-Immune Axes: How the nervous system and immune system communicate to regulate (or enable) growth.

Figure 2: The "Clouds of Complexity" - systemic interactions reshaping our understanding of cancer. Source: Hanahan, Cell 2026 (CC BY 4.0)

2. "Accessories to the Crime"

We've known about the microenvironment for a while, but the 2026 framework explicitly categorizes normal cells (fibroblasts, endothelial cells, immune cells) as "Hallmark-Conveying Cells."
These aren't just bystanders; they are recruited and reprogrammed to perform specific hallmark functions for the cancer cells. The tumor outsources its dirty work.

3. Mechanism-Guided Co-Targeting

The therapeutic takeaway is clear: targeting a single mutation is rarely enough. The new framework pushes for co-targeting:

  • Hit the cancer cell's driver mutation.
  • Plus block the "accessory" cells support.
  • Plus disrupt the systemic "enabling" factors.

Figure 3: Mechanism-guided co-targeting approaches in cancer therapy. Source: Hanahan, Cell 2026 (CC BY 4.0)

Why It Matters for Bioinformaticians

For those of us analyzing data, this widens the scope of "relevant features."

  • Don't filter out the 'host' reads: That fibroblast signal in your single-cell data might be the key to the tumor's survival.
  • Integrate clinical metadata: Age, BMI, and metabolic status are not just covariates to correct for—they are mechanistic drivers.

The Paper

Hallmarks of cancer—Then and now, and beyond
Douglas Hanahan, Cell (2026)
Read on PubMed